PMID: 8610141Apr 2, 1996Paper

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

Proceedings of the National Academy of Sciences of the United States of America
H FakhraiR E Sobol

Abstract

Like human gliomas, the rat 9L gliosarcoma secretes the immunosuppressive transforming growth factor beta (TGF-beta). Using the 9L model, we tested our hypothesis that genetic modification of glioma cells to block TGF-beta expression may enhance their immunogenicity and make them more suitable for active tumor immunotherapy. Subcutaneous immunizations of tumor-bearing animals with 9L cells genetically modified to inhibit TGF-beta expression with an antisense plasmid vector resulted in a significantly higher number of animals surviving for 12 weeks (11/11, 100%) compared to immunizations with control vector-modified 9L cells (2/15, 13%) or 9L cells transduced with an interleukin 2 retroviral vector (3/10, 30%) (P < 0.001 for both comparisons). Histologic evaluation of implantation sites 12 weeks after treatment revealed no evidence of residual tumor. In vitro tumor cytotoxicity assays with lymph node effector cells revealed a 3- to 4-fold increase in lytic activity for the animals immunized with TGF-beta antisense-modified tumor cells compared to immunizations with control vector or interleukin 2 gene-modified tumor cells. These results indicate that inhibition of TGF-beta expression significantly enhances tumor-cell immunogenic...Continue Reading

References

Aug 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·P PisaR Kiessling
Jun 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·J TrojanJ Ilan
Oct 1, 1991·Immunology Today·T RoszmanW Brooks
Dec 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·C A KruseD Bellgrau
Aug 1, 1989·Journal of Neurosurgery·M C KuppnerN de Tribolet
Dec 1, 1989·Journal of Neurosurgery·M S MahaleyB B Peace
Jan 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·S K HanksR W Holley
Aug 26, 1993·Journal of Immunological Methods·L A RandallA R Mire-Sluis

❮ Previous
Next ❯

Citations

Jul 12, 2002·Journal of Clinical Laboratory Analysis·Antonia CostacurtaSalvatore Cantaro
Oct 1, 1996·Journal of Mammary Gland Biology and Neoplasia·B A Arrick
Feb 5, 2003·Journal of Biomedical Science·Ian F Parney, Lung-Ji Chang
Aug 24, 1999·Medical Oncology·F Salazar-Onfray
Sep 28, 2005·Cancer Immunology, Immunotherapy : CII·Jen-Jung PanSteven J Greenberg
Jun 10, 2010·Cancer Immunology, Immunotherapy : CII·Maha Zohra LadjemiIsabelle Navarro-Teulon
Feb 9, 2008·Neurosurgical Review·Lee A SelznickJohn Sampson
Sep 5, 2006·Cancer Metastasis Reviews·Sonia B Jakowlew
Aug 20, 2010·Pharmaceutical Research·Yogita KrishnamachariAliasger K Salem
Jul 14, 1998·In Vitro Cellular & Developmental Biology. Animal·C A KruseB C Liang
Mar 20, 2002·Current Neurology and Neuroscience Reports·D B Paul, C A Kruse
Jul 13, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Jeroen T BuijsTheresa A Guise
Feb 19, 2004·Brain Research. Molecular Brain Research·Naibedya ChattopadhyayEdward M Brown
May 10, 2003·Brain Research. Brain Research Reviews·Paul R WalkerPierre Yves Dietrich
Dec 4, 2001·Advanced Drug Delivery Reviews·Y S Haviv, D T Curiel
Nov 26, 1999·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·M M ValterT Pietsch
Dec 28, 1999·Microbes and Infection·M Reiss
Dec 22, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Neil SenzerJohn Nemunaitis
Jun 24, 2006·Nature Reviews. Cancer·Brian Bierie, Harold L Moses
May 12, 2004·Nature Reviews. Drug Discovery·Jeremy N Rich, Darell D Bigner
Dec 2, 2004·Nature Reviews. Drug Discovery·Jonathan M YinglingJ Scott Sawyer
Jul 9, 2002·Clinical and Experimental Immunology·D L ShawlerR E Sobol
Sep 13, 2002·Immunology·Paul R WalkerPierre-Yves Dietrich
May 18, 1999·Current Opinion in Oncology·A Weyerbrock, E H Oldfield
Mar 17, 2012·Journal of Immunotherapy·Huafeng WeiIngegerd Hellström
Nov 5, 1997·Annals of the New York Academy of Sciences·P Y DietrichN de Tribolet
Mar 23, 2006·Annual Review of Immunology·Ming O LiRichard A Flavell
Jan 5, 2002·In Vitro Cellular & Developmental Biology. Animal·M Kingsley-KallesenA Rizzino
Apr 8, 2009·Critical Reviews in Immunology·Hideho OkadaMitsugu Fujita

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.